We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Diagnostics Company Wins Patent Battle

By Labmedica staff writers
Posted on 20 Oct 2006
The United States Patent and Trademark Office (USPTO) has ruled in favor of Stanbio Laboratory (Boerne, TX, USA), initially rejecting claims of its competitor HemoCue (Lake Forest, CA, USA).

All seven claims of HemoCue's microcuvette patent (#5,674,457) were initially rejected. More...
The microcuvette is a blood-collecting and -testing device used with Stanbio Laboratory's HemoPoint H2 photometer. In April 2006, Stanbio Laboratory filed a cross-complaint alleging that HemoCue, Inc., engaged in unfair business practices against Stanbio. According to Stanbio's cross-complaint, HemoCue was telling customers and potential customers that Stanbio was legally barred from selling its hemoglobin meters and microcuvettes.

"This is a tremendous victory for our side regarding our rights to sell our HemoPointH2 hemoglobin testing system,” said William Pippin, CEO of Stanbio Laboratory. "We believe the panel's finding fully supports our case that HemoCue's patent is invalid. There has been a great deal of misinformation circulated about patents once we introduced our HemoPoint H2 hemoglobin testing system.”

Stanbio's HemoPoint H2 hemoglobin system is widely used in hospitals, physician office laboratories, blood banks, as a screening test for anemia. The company manufactures and sells testing and diagnostic devices for clinical chemistry, pregnancy, drugs of abuse, serology, urinalysis, microbiology assays, and point-of-care blood hemoglobin tests, with customers in 70 countries around the world.



Related Links:
Stanbio Laboratory
HemoCue

Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Hemodynamic System Monitor
OptoMonitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.